Drugs / TLC599
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02803307 | Jun 2015 → Nov 2016 | osteoarthritis, knee | Taiwan Liposome Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03754049 | Jan 2019 → Nov 2023 | osteoarthritis, knee | Taiwan Liposome Company | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04123561 | Nov 2019 → Feb 2022 | osteoarthritis, knee | Taiwan Liposome Company | Completed | Met primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-04-27 | TLC Biopharmaceuticals, Inc. | Results TLC BioSciences Presents Late-Breaking Poster Data on TLC599 Structural Benefit at OARSI 2026 World Congress tlcbio.com ↗
Results showed that TLC599-treated patients experienced approximately half the degree of joint space narrowing compared to those receiving placebo over one year. |
| 2026-04-13 | TLC Biopharmaceuticals, Inc. | Results TLC BioSciences to Present Late-Breaking Poster on TLC599 Structural Benefit Data at OARSI 2026 World Congress tlcbio.com ↗
Results showed that patients treated with TLC599 experienced approximately half the degree of joint space narrowing compared to placebo-treated patients, suggesting a potential structural benefit. |
| 2023-11-20 | TLC Biopharmaceuticals, Inc. | Results Highlights of Oral Presentation at ACR’s Late Breaking Abstracts Session tlcbio.com ↗
Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology (ACR) Annual Meeting last week. |
| 2023-11-08 | TLC Biopharmaceuticals, Inc. | Results TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR tlcbio.com ↗
The data from this pivotal Phase 3 trial demonstrates the sustained efficacy and safety of TLC599 out to 52 weeks. |
| 2022-03-07 | TLC Biopharmaceuticals, Inc. | Results TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy tlcbio.com ↗ |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-19 | TLC Biopharmaceuticals, Inc. | TLC BioSciences Completes Phase 2 PK Trial for TLC599 in Japan tlcbio.com ↗ |
| 2026-04-27 | TLC Biopharmaceuticals, Inc. | TLC BioSciences Presents Late-Breaking Poster Data on TLC599 Structural Benefit at OARSI 2026 World Congress tlcbio.com ↗ |
| 2026-04-13 | TLC Biopharmaceuticals, Inc. | TLC BioSciences to Present Late-Breaking Poster on TLC599 Structural Benefit Data at OARSI 2026 World Congress tlcbio.com ↗ |
| 2023-11-20 | TLC Biopharmaceuticals, Inc. | Highlights of Oral Presentation at ACR’s Late Breaking Abstracts Session tlcbio.com ↗ |
| 2023-11-08 | TLC Biopharmaceuticals, Inc. | TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR tlcbio.com ↗ |
| 2022-03-07 | TLC Biopharmaceuticals, Inc. | TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy tlcbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLC599 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02803307 ↗ |
| Modality | Other / unclassified | “proprietary lipid formulation” NCT03754049 ↗ |
| Route | Other | “via IA injection” NCT03754049 ↗ |